MINNEAPOLIS--(BUSINESS WIRE)--Medtronic Inc. (NYSE:MDT) today announced the start of its CONNECTSM trial, which will further substantiate the impact of Medtronic’s most advanced devices with Conexus™ Wireless Telemetry remote monitoring capabilities. The trial will assess how effectively the use of the Medtronic CareLink® Network to remotely monitor patients with the Concerto™ cardiac resynchronization therapy-defibrillator (CRT-D) and Virtuoso™ implantable cardioverter-defibrillator (ICD) enables better patient care and reduces unnecessary healthcare costs.
